Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.59 |
| ▸ | PAM | P19021 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PRKCA | P17252 | 1/20 | 0.45 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.45 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.45 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9876160 | 0.98 | DGKA (0.62) | DGKAPAMTSHRMAPTLMNA | |
| SCHEMBL9400196 | 0.98 | DGKA (0.62) | DGKAPAMTSHRMAPTLMNA | |
| SCHEMBL3216532 | 0.98 | DGKA (0.62) | DGKAPAMTSHRMAPTLMNA | |
| SCHEMBL8945616 | 0.98 | DGKA (0.62) | DGKAPAMTSHRMAPTLMNA | |
| SCHEMBL8945733 | 0.98 | DGKA (0.62) | DGKAPAMTSHRMAPTLMNA | |
| SCHEMBL9095809 | 0.94 | DGKA (0.50) | DGKAPAMTSHRMAPTLMNA | |
| SCHEMBL508579 | 0.89 | DGKA (0.41) | DGKAPAMTSHRMAPTLMNA | |
| SCHEMBL733969 | 0.85 | ALDH1A1 (0.48) | DGKAPAMTSHRMAPTLMNA | |
| SCHEMBL10105403 | 0.85 | TSHR (0.40) | DGKAPAMTSHRMAPTLMNA | |
| SCHEMBL355770 | 0.83 | DGKA (0.63) | DGKAPAMTSHRMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050154008-A1 | Aryl fused substituted 4-oxy-pyridines | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE (US) | 2005-07-14 | — | — | US | claimed |
| US-20020035121-A1 | Aryl fused substituted 4-oxy-pyridines | CAI GUOLIN (US) | 2002-03-21 | — | — | US | claimed |
| JP-11098999-A | — | — | None | — | — | JP | disclosed |
| CN-107106700-B | Peptidomimetic compounds and antibody-drug conjugates thereof | 基因泰克公司 | 2020-10-30 | — | — | CN | disclosed |
| CN-107106700-A | Peptide simulated compound and its antibody drug conjugate | 基因泰克公司 | 2017-08-29 | — | — | CN | disclosed |
| US-7371752-B2 | Aryl fused substituted 4-oxy-pyridines | NEUROGEN CORPORATION (US) | 2008-05-13 | — | — | US | disclosed |
| US-20050154008-A1 | Aryl fused substituted 4-oxy-pyridines | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE (US) | 2005-07-14 | — | — | US | disclosed |
| US-6828329-B2 | Agonists, antagonists for gamma-aminobutyric acid brain receptors useful in diagnosis and treatment of anxiety depressionm, down syndrome, sleep and seizure disorders | NEUROGEN CORPORATION | 2004-12-07 | — | — | US | disclosed |
| US-20020035121-A1 | Aryl fused substituted 4-oxy-pyridines | CAI GUOLIN (US) | 2002-03-21 | — | — | US | disclosed |
| JP-2000189187-A | PRODUCTION OF OPTICALLY ACTIVE 1,1,1-TRIFLUORO-2-ALKANOL | CHISSO CORP | 2000-07-11 | — | — | JP | disclosed |
| US-5973214-A | Method for producing an optically active 2-alkanol | CHISSO CORPORATION (JP) | 1999-10-26 | — | — | US | disclosed |
| EP-0908522-A1 | A method for producing an optically active 2-alkanol | CHISSO CORPORATION (JP) | 1999-04-14 | — | — | EP | disclosed |
| JP-H1198999-A | PRODUCTION OF OPTICALLY ACTIVE 2-ALKANOL | CHISSO CORP | 1999-04-13 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154008-A1 | Aryl fused substituted 4-oxy-pyridines | CHRNA7, CHRNA4, GABRA6 | DGKA 2295/4885PAM 1392/4885TSHR 578/4885 |
| US-20020035121-A1 | Aryl fused substituted 4-oxy-pyridines | GABRA4, GABRA6, GABRG2 | DGKA 2174/4885PAM 1387/4885TSHR 634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.